NURS 5434/ NURS5434 Final Exam (NEW 2026 Update) – Family III (FNP 3) Guide | Questions & Answers | Grade A| 100% Correct (Verified Solutions)- UTA

NURSl 5434/l NURS5434l Finall Examl
(NEWl 2026l Update)l –l Familyl IIIl (FNPl
3)l Guidel |l Questionsl &l Answersl |l Gradel
A|l 100%l Correctl (Verifiedl Solutions)-l
UTA


QUESTION
statinl dosingl basedl onl ASCVDl percentage

Answer:
<5%l -l lifestylel mods
5-7.5%l -l lifestyle,l considerl statinl ifl riskl enhancers
7.5-20%l -l moderatel intensityl statin
>20%l -l highl intensityl statinl

CACl scoresl canl helpl decidel inl borderlinel casesl (CACl >100l startl al statin)



QUESTION
Highl Intensityl Statin

Answer:
atorvastatinl 40-80l mg
rosuvastatinl 20-40l mg
reducesl LDLl >50%



QUESTION
Moderatel Intensityl Statin

Answer:

,atorvastatinl 10-20mg
rosuvastatinl 5-10mg
simvastatinl 20-40mg
pravastatinl 40-80mg
reducesl LDLl 30-49%



QUESTION
Lowl intensityl statin

Answer:
simvastatinl 10mg
pravastatinl 10-20mg
reducesl LDLl <30%



QUESTION
whenl tol addl ezetimibe

Answer:
-l patientsl withl clinicall ASCVDl whol arel alreadyl onl maximuml statinl therapyl andl LDLl
>70l orl ifl needl >50%l dropl
-l patientsl withl LDLl >190l atl baselinel orl withl LDL>100l onl maxl statinl

whyl addl ezetimibel first?
-l welll tolerated,l inezpensive,l lowersl LDLl 20-25%



QUESTION
whenl tol addl PCSK9

Answer:
-l ptsl withl clinicall ASCVDl atl veryl highl riskl whol arel onl maxl statinl therapyl andl
ezetimibel butl stilll havel LDLl >70l
-l ptl withl familiall hypercholesterolemial (LDL>190)l andl stilll >100l onl maxl statinl andl
ezetimibe

,QUESTION
PCSK9l Inhibitors

Answer:
alirocumab,l evolocumab
injectiblel andl expensive
decreasel LDLl ~60%
savedl forl highestl riskl people



QUESTION
whatl countsl asl "veryl highl riskl ASCVD"

Answer:
multiplel majorl ASCVDl eventsl (MI,l stroke,l PAD)l ORl 1l majorl ASCVDl eventl andl
multiplel highl riskl conditionsl likel DM,l HTN,l smoking,l CKD,l agel >65

recentl ACSl withinl lastl year,l Hxl MIl orl stroke,l symptomaticl PAD,l ABIl <8.5,l previousl
revascularizationl orl amputation



QUESTION
Statinl Sidel Effects

Answer:
Mostl commonl -l musclel aches,l cramps,l weaknessl

Rhabdomyolysisl isl rarel -l darkl urine,l markedl CKl elevationl

Liverl impactl -l statinsl canl causel transientl increasel inl ALT/AST,l onlyl monitorl LFTsl ifl
symptomatic



QUESTION
CACl Scoring

Answer:
Coronaryl Calciuml Screeningl

, CTl withoutl contrastl thatl measuresl thel amountl andl locationl ofl calcifiedl coronaryl arteryl
plaquel (doesn'tl measurel softl plaquel whichl isl thel kindl mostl likelyl tol rupture)
-l providesl strongl evidencel ofl riskl

0l -l nol evidencel ofl CAD
1-10l -l minimall evidence
11-100l mildl evidence,l lookl atl riskl factors
101-400l moderatel evidencel ofl CAD
>400l extensivel evidencel ofl CAD



QUESTION
Howl tol managel myalgias

Answer:
1.l stopl statinl forl 2-4l weeksl tol seel ifl sxl resolve
2.l checkl CK,l TSH,l vitaminl D,l renall functionl
3.l ifl sxl resolve,l startl atl lowerl dosel orl tryl differentl statinl (pravastatinl andl rosuvastatinl
arel LESSl lipophillic)
4.l considerl alternatel dayl dosing
5.l ifl intolerablel despitel tryingl 2-3l statins,l considerl ezetimibel orl PCSK9l inhibitorsl ifl
highl risk



QUESTION
Statinl Followl Up

Answer:
Repeatl lipidl testingl inl 4-12l weeksl afterl tol monitorl adherencel andl biologicall response
Thenl checkl everyl 3-12l monthsl froml there
CKl andl ALTl notl necessaryl unlessl symptomatic



QUESTION
Pediatricl Lipidl Screening

Answer:
Agel 9-11l andl 17-21